1
|
Shi Y, Lain E, Frasson N, Ortiz-Brugués A, Stennevin A. The Real-World Effectiveness and Tolerability of a Soothing Cream Containing the Postbiotic Aquaphilus dolomiae Extract-G2 for Skin Healing. Dermatol Ther (Heidelb) 2024; 14:697-712. [PMID: 38451421 DOI: 10.1007/s13555-024-01119-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 02/13/2024] [Indexed: 03/08/2024] Open
Abstract
INTRODUCTION In vitro and pre-marketing clinical data have shown the healing properties of a postbiotic extract from Aquaphilus dolomiae (ADE-G2). The effectiveness and tolerability of an ADE-G2-based cream were therefore evaluated for the management of minor skin impairment and wound healing in a large population of subjects in routine clinical practice. METHODS A real-world, international, pre-post comparative study was conducted in infants, children, and adults with various types of superficial skin impairment who used the study product daily for around 3 weeks according to their dermatologist's advice. Immediate and follow-up changes in dermatologic signs and symptoms were assessed through clinical scoring. User satisfaction, overall product effectiveness, and tolerability were also evaluated. Analyses were performed in the whole study population and in subject subgroups according to skin impairment type and age. RESULTS Overall, 1317 subjects (83.1% adults, 72.0% female) were included. Dermatologists reported effectiveness and "good" or "very good" tolerability of the cream in 93.8% (1221/1302) and 98.5% (1278/1297) of subjects, respectively. Immediate symptom relief after the first application was reported by 88.3% (849/962) of subjects. After several weeks of regular use (16.7 ± 11.6 days), dermatologic signs and symptoms significantly improved in the whole study population and in the subgroups, with mean decreases in severity scores ranging from -34.5% to -92.5% (p < 0.0001). The smallest improvements were found in subjects with oncologic treatment-related skin impairment. At study end, most users (> 95%) were "very satisfied" or "satisfied" with the cream and found that skin healing was rapid and of good quality. CONCLUSION The ADE-G2-based cream proved to be effective and well tolerated in real-life conditions for the management of minor skin impairment in a large and varied cohort of subjects. This product, used as a standalone or adjunctive regimen, can help accelerate the healing of various types of superficial skin impairment.
Collapse
Affiliation(s)
- Yuling Shi
- Department of Dermatology, Shanghai Skin Disease Hospital and Institute of Psoriasis, Tongji University School of Medicine, Shanghai, China
| | - Edward Lain
- Sanova Dermatology, Austin Institute for Clinical Research, Austin, TX, USA
| | - Nicolas Frasson
- Clinique Du Dr Ster, 9 Avenue Dr Jean Ster, 34240, Nîmes, France
| | - Ariadna Ortiz-Brugués
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, 81500, Lavaur, France
| | - Aline Stennevin
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, 81500, Lavaur, France.
| |
Collapse
|
2
|
Wollenberg A, Giménez-Arnau AM, Stennevin A, Ortiz-Brugués A. Real-world effectiveness and tolerability of a cream containing postbiotic Aquaphilus dolomiae extract-G3 in subjects with sensitive facial skin. Eur J Dermatol 2024; 34:79-88. [PMID: 38557463 DOI: 10.1684/ejd.2024.4637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Previous studies indicate that a postbiotic extract from Aquaphilus dolomiae (ADE-G3) improves skin barrier function and relieves neuroinflammation. Evaluation of an ADE-G3-based soothing cream for managing sensitive facial skin. This real-world, international, pre-post comparative study involved adults with sensitive facial skin who used the study product once or twice daily for two to three months according to usual practice. Subjects reported changes in perceived clinical symptoms using self-administered questionnaires. Physicians assessed changes in xerosis severity, overall product effectiveness and tolerability. User satisfaction and quality of life (QoL) assessments, and subgroup analyses according to the factors triggering sensitive skin were also conducted. In total, 2,382 subjects with sensitive facial skin (female: 79%; median age: 40 years) were included. An immediate skin soothing effect after the first ADE-G3-based cream application was reported by 93% of subjects, and improvements in symptoms were reported in 94% after a mean of nine days of product use. After several months of use (mean: 71±21 days), xerosis severity and dermatological-related QoL significantly improved in the whole study population and in the subgroups (p<0.001). At the end of the study, 92% of users were satisfied with the product and 95% reported improvements in their overall skin condition. Physicians found the cream to be effective and well tolerated in 92% and 98% of subjects, respectively. Regular use of the ADE-G3-based cream was shown to be effective in real-world management of sensitive facial skin, regardless of the factors involved in triggering skin sensitivity.
Collapse
Affiliation(s)
- Andreas Wollenberg
- Department of Dermatology and Allergology, Ludwig-Maximilian University, D-80337 Munich, Germany, and Department of Dermatology and Allergology, University Hospital Augsburg, D-86179 Augsburg, Germany
| | - Ana Maria Giménez-Arnau
- Department of Dermatology, Hospital del Mar-IMIM, University Pompeu Fabra, 08003 Barcelona, Spain
| | - Aline Stennevin
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, 81500 Lavaur, France
| | - Ariadna Ortiz-Brugués
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, 81500 Lavaur, France, Department of Dermatology and Venereology, Hospital La Paz, 28046 Madrid, Spain
| |
Collapse
|
3
|
Bageorgou F, Li L, Beausillon C, Stennevin A, Ortiz-Brugués A, Saurat JH. Tolerability and effectiveness of a dermocosmetic product containing Silybum marianum fruit extract in adolescents and young adults with acne-prone skin: An international, phase IV, longitudinal study. J Cosmet Dermatol 2023. [PMID: 36973603 DOI: 10.1111/jocd.15705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 02/07/2023] [Accepted: 02/23/2023] [Indexed: 03/29/2023]
Abstract
BACKGROUND Dermocosmetic products are often used to maintain or enhance the tolerance and effectiveness of medical anti-acne therapies. Recent discoveries about the pathophysiology of acne-prone skin indicate that skincare products may help maintain homeostasis around the sebaceous gland progenitor cells, thereby preventing microcomedone formation. AIMS To evaluate the tolerance and effectiveness of a dermocosmetic product containing Silybum marianum fruit extract (SMFE) in adolescents and young adults with acne-prone skin. PATIENTS/METHODS This real-life, international, observational, multicenter study was conducted in patients aged 12-25 years with mild-to-moderate acne. Patients (N = 4230) used the product twice daily for 8-12 weeks, either alone before ("initial group") or after an anti-acne therapy ("maintenance group"), or in association with their usual prescribed anti-acne therapies ("association group"). The tolerance, effectiveness, and cosmetic properties of the product were assessed. Patient quality of life (QoL) was also evaluated. RESULTS Dermatologists rated the tolerance of the product as "good" or "very good" in about 95% of the patients and the effectiveness of the product as "effective" or "highly effective" in about 80% of the patients, with a significant reduction in the mean global evaluation of acne (GEA) grade (-36% ± 39%, p < 0.0001) at study end. The QoL of most patients (80%) improved by the end of the study, and the majority (79% to 94%) appreciated the cosmetic properties of the product. Overall, the product was a clinical success in >84% of patients. CONCLUSIONS This dermocosmetic product can be used by adolescents and young adults with acne-prone skin to limit the initial or chronic use of medical anti-acne therapies.
Collapse
Affiliation(s)
| | - Li Li
- Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China
| | | | - Aline Stennevin
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Lavaur, France
| | | | | |
Collapse
|
4
|
Mias-Vigouroux C, Questel E, Assi A, Tfayli A, Stennevin A, Bessou-Touya S, Duplan H. 257 Clinical skin moisturizing property of the AVENE thermal spring water is associated with water capture and higher lipid organization in the stratum corneum. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
5
|
Vendrely V, Mayor-Ibarguren A, Stennevin A, Ortiz-Brugués A. An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study. Dermatol Ther (Heidelb) 2022; 12:683-699. [PMID: 35107817 PMCID: PMC8941027 DOI: 10.1007/s13555-022-00685-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2021] [Accepted: 01/20/2022] [Indexed: 11/30/2022] Open
Abstract
INTRODUCTION Xerosis is a common skin side effect of current anticancer therapies, including chemotherapy, targeted therapy, radiotherapy, and hormonotherapy. We evaluated the effectiveness of an emollient PLUS containing an Aquaphilus dolomiae extract (ADE-G1) for the management of xerosis in adult patients treated for cancer. METHODS This real-world, prospective, observational, multicenter study involved 319 xerotic cancer patients, who were prescribed the study product according to the usual practice of their physician. The practitioner assessed xerosis severity and objective clinical signs, and the patients assessed subjective clinical signs and the impact of their skin condition on their quality of life, at inclusion and after around 4 weeks of use. Overall effectiveness and tolerance were assessed at the end of the study. Clinical success was defined by the combination of several of these effectiveness outcomes. RESULTS Daily application of the emollient PLUS reduced xerosis severity in 62.7% of patients (p < 0.0001). The mean total severity scores for objective and subjective clinical signs were reduced by 67.7% and 57.4% (p < 0.0001), respectively, compared with baseline. The mean Dermatology Life Quality Index (DLQI) score also significantly improved at the end of follow-up (-56.6%, p < 0.0001). The product was rated as "effective" or "very effective" by the physician for over 80% of patients, regardless of the initial severity grade of xerosis. Overall clinical success was achieved in 73.7% of patients. A trend toward higher effectiveness and clinical success was observed in patients under hormonotherapy. The study product was well tolerated, regardless of the anticancer therapy being received. CONCLUSION This study shows that the emollient PLUS containing ADE-G1 is an effective treatment for xerosis in cancer patients, regardless of the initial grade of xerosis and the anticancer treatment received.
Collapse
Affiliation(s)
| | | | - Aline Stennevin
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, 81500, Lavaur, France
| | - Ariadna Ortiz-Brugués
- Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmétique, Les Cauquillous, 81500, Lavaur, France.
| |
Collapse
|
6
|
Pachuta Węgier L, Kubiak M, Liebert A, Clavel T, Montagne A, Stennevin A, Roye S, Boudribila A. Ferrous sulfate oral solution in young children with iron deficiency anemia: An open-label trial of efficacy, safety, and acceptability. Pediatr Int 2020; 62:820-827. [PMID: 32191814 PMCID: PMC7496601 DOI: 10.1111/ped.14237] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 03/03/2020] [Accepted: 03/16/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND This study evaluated the efficacy, safety, and acceptability of a new ferrous sulfate oral solution (Tardyferon® 20 mg/mL) in young children with mild or moderate iron deficiency anemia (IDA). METHODS This was a multicenter, national, single-arm, open-label study. Children aged 6-53 months presenting with mild or moderate IDA (i.e., blood hemoglobin (Hb) ranging from 7.0 to 10.9 g/dL and serum ferritin <12 ng/mL) were eligible for inclusion. The ferrous sulfate heptahydrate solution (2 mg/kg/day) was administered orally for 3 months. If normalization of either Hb or ferritin was not achieved at month 3 the treatment was continued for another 3 months. RESULTS Of the 100 children screened, 21 aged 6-17 months were included and received the study treatment, and 19 were analyzed for hematologic outcomes at month 3. Only one patient continued treatment for the additional 3 months. At month 3, mean ± SD Hb and ferritin levels were 12.0 ± 0.7 g/dL and 31.5 ± 19.4 ng/mL, respectively. Hemoglobin and ferritin levels were normalized in 95% (18/19) and 84% (16/19) of the patients, respectively. Treatment compliance and levels of satisfaction of both the parents and the investigators were high. Overall, 33.3% of patients (7/21) experienced at least one adverse event. Only one patient (4.8%) experienced a drug-related adverse event (upper abdominal pain). CONCLUSIONS A 2 mg/kg daily dose of the new oral ferrous sulfate heptahydrate solution provides substantial therapeutic benefit with high levels of tolerability in young children who have mild or moderate IDA.
Collapse
Affiliation(s)
| | | | | | | | - Agnès Montagne
- Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France
| | - Aline Stennevin
- Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France
| | - Sandrine Roye
- Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France
| | - Asmaa Boudribila
- Clinical Development Department, Institut de Recherche Pierre Fabre, CRDPF, Toulouse, France
| |
Collapse
|
7
|
Gomes B, ROBICHON C, Pillon A, Annereau JP, Pourtau S, Blanchet JC, Stennevin A, Bedjeguelal K, Rochaix P, Garrido-Stowhas I, Lamant L, Meyer N, Guilbaud N, Bailly C, Kruczynski A. Abstract 1219: Patient-derived tumor models of resistant metastatic melanoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-1219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Despite recent advances in the therapy of metastatic melanoma, patients have a poor prognosis and die from their disease, with a 5-year survival rate of less than 20%. Metastatic melanoma remains mainly chemoresistant, therefore novel therapeutic strategies to overcome primary or acquired resistance are required. In order to more reliably predict clinical activity of novel compounds in melanoma patients, we have established a series of patient-derived tumor xenograft models (PDTX). Surgically resected tumors samples were obtained from patients with metastatic melanoma before or after treatment. Twenty-three samples from 9 patients and representative of various stages of disease progression were implanted onto immunocompromised NSG mice. A high take rate of 56% (13/23 samples) was observed, corresponding to the samples from 8/9 patients. Tumor take was independent of tumor size, histologic parameters and B-RAF status. The first tumor generation (graft) harbouring the patient-derived sample (G1), as well as the subsequent generations were characterized for each PDTX. The pattern of expression of the melanoma differentiation markers S100, melanosome, tyrosinase and melan-A were maintained over the serial transplantations. These models also closely recapitulated the heterogeneity of patient tumors in terms of cell morphology over the first generations (G1-G5), but this heterogeneity tended to decrease with the number of generations. One of these primary PDTXs, MEL-11 exhibited metastatic spread in axillary lymph nodes. Furthermore 2 other primary melanoma PDTXs, MEL-1 and MEL-3, established from primary refractory patient metastatic melanoma retained complete resistance to temozolomide and vemurafenib, the two reference drugs for melanoma. The MEL-3 model was selected to assess the anti-melanoma activity of F-RK-4, a novel multi-kinases inhibitor (including inhibition of mutated B-RAF). Multiple i.p. administrations of F-RK-4 resulted in a significant antitumor activity, as reflected by a tumor growth inhibition of 50%. Overall these results suggest that these patient-derived melanoma xenografts represent a useful preclinical tool to identify novel anti-melanoma therapeutics.
Citation Format: Bruno Gomes, Céline ROBICHON, Arnaud Pillon, Jean-Philippe Annereau, Sandrine Pourtau, Jean-Christophe Blanchet, Aline Stennevin, Karim Bedjeguelal, Philippe Rochaix, Ignacio Garrido-Stowhas, Laurence Lamant, Nicolas Meyer, Nicolas Guilbaud, Christian Bailly, Anna Kruczynski. Patient-derived tumor models of resistant metastatic melanoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1219. doi:10.1158/1538-7445.AM2014-1219
Collapse
Affiliation(s)
- Bruno Gomes
- 1Institute de Recherche Pierre Fabre, Toulouse, France
| | | | - Arnaud Pillon
- 1Institute de Recherche Pierre Fabre, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Annereau JP, Brel V, Riquet W, Créancier L, Vandenberghe I, Fournier E, Robichon C, Stennevin A, Offrete V, Lacastaigneratte L, Gomes B, Kruczynski A, Bailly C, Guilbaud N. Abstract 988: F14512, a novel vectorized topoiserase II inhibitor, bypasses MDR1 mediated resistance. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
F14512 is a novel polyamine-vectorized topoisomerase II inhibitor currently in phase 1/2 clinical trial in acute myeloid leukemia (AML). Since ABCB1 (also called P-glycoprotein or MDR1) has been reported to be expressed at high levels in patients with resistant leukaemia cells, and constitutes a pejorative marker of therapy, we decided to investigate whether F14512 could be exported by ABCB1 or other ABC transporters susceptible to confer drug resistance to chemotherapy, such as MRP1. In addition, we established a F14512-resistant cell line to study the mechanism of resistance to the drug.
With membrane preparation enriched in functional MDR1, we found that F14512 was unable to stimulate the ATPase activity of this transporter. Using a cellular assay over expressing MDR1 transporter by recombinant transfection of MDCKII cells, F14512 was detectable, but the intracellular level was unchanged regardless of the MDR1 status or in presence of MDR1 competitors. Consistently, iterative selection of a F14512-resistant A-549 cell line with 36 cycles of F14512 at cytotoxic doses (0.5 EC50) over 9 months, led to only moderate shift of resistance (9 fold). In the resulting selected A-549 subclones, MDR1, MRP1 and ABCG2 were detectable at the basal level.
The ability of F14512 to bypass MDR1 was finally assessed in a vinorelbine-resistant P388 model overexpressing high level of functional ABCB1 as indicated with the positive rhodamine export assay and cross resistance to MDR1 substrate. Moreover, F14512 displays strong antileukemic activity in MDR1-positive P388 cells in vitro and additional in vivo measurements are in progress.
In conclusion, the data concur to show that the antitumor activity of the targeted cytotoxic agent F14512 is not impacted by the MDR1 status of cancer cells. MDR1 clearly does not affect the potency of F14512 and this characteristic augurs well for the ongoing development of the drug in AML patients.
Citation Format: Jean Philippe Annereau, Viviane Brel, William Riquet, Laurent Créancier, Isabelle Vandenberghe, Emmanuel Fournier, Céline Robichon, Aline Stennevin, Vanessa Offrete, Laurence Lacastaigneratte, Bruno Gomes, Anna Kruczynski, Christian Bailly, Nicolas Guilbaud. F14512, a novel vectorized topoiserase II inhibitor, bypasses MDR1 mediated resistance. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 988. doi:10.1158/1538-7445.AM2013-988
Collapse
Affiliation(s)
| | - Viviane Brel
- Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | | | | | | | | | | | | - Bruno Gomes
- Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | |
Collapse
|
9
|
Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L, Meyer N, Gairin JE, Guilbaud N, Annereau JP. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One 2012; 7:e36762. [PMID: 22675422 PMCID: PMC3360047 DOI: 10.1371/journal.pone.0036762] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Accepted: 04/12/2012] [Indexed: 12/29/2022] Open
Abstract
Metastatic melanoma is the most aggressive skin cancer. Recently, phenotypically distinct subpopulations of tumor cells were identified. Among them, ABCB5-expressing cells were proposed to display an enhanced tumorigenicity with stem cell-like properties. In addition, ABCB5+ cells are thought to participate to chemoresistance through a potential efflux function of ABCB5. Nevertheless, the fate of these cells upon drugs that are used in melanoma chemotherapy remains to be clarified. Here we explored the effect of anti-melanoma treatments on the ABCB5-expressing cells. Using a melanoma xenograft model (WM266-4), we observed in vivo that ABCB5-expressing cells are enriched after a temozolomide treatment that induces a significant tumor regression. These results were further confirmed in a preliminary study conducted on clinical samples from patients that received dacarbazine. In vitro, we showed that ABCB5-expressing cells selectively survive when exposed to dacarbazine, the reference treatment of metastatic melanoma, but also to vemurafenib, a new inhibitor of the mutated kinase V600E BRAF and other various chemotherapeutic drugs. Our results show that anti-melanoma chemotherapy might participate to the chemoresistance acquisition by selecting tumor cell subpopulations expressing ABCB5. This is of particular importance in understanding the relapses observed after anti-melanoma treatments and reinforces the interest of ABCB5 and ABCB5-expressing cells as potential therapeutic targets in melanoma.
Collapse
Affiliation(s)
- Marine Chartrain
- UMR 2587, CNRS-Pierre Fabre, Institut des Sciences et Technologies du Médicament de Toulouse (ISTMT), Toulouse, France
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| | - Joëlle Riond
- UMR 2587, CNRS-Pierre Fabre, Institut des Sciences et Technologies du Médicament de Toulouse (ISTMT), Toulouse, France
- USR 3388, CNRS-Pierre Fabre, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
- * E-mail:
| | - Aline Stennevin
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| | - Isabelle Vandenberghe
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| | - Bruno Gomes
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| | | | | | - Jean Edouard Gairin
- UMR 2587, CNRS-Pierre Fabre, Institut des Sciences et Technologies du Médicament de Toulouse (ISTMT), Toulouse, France
- UMR152 IRD-UPS “PHARMA-DEV”, Faculté de Pharmacie - Université Toulouse III - Paul Sabatier, Toulouse, France
| | - Nicolas Guilbaud
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| | - Jean Philippe Annereau
- Centre de Recherche en Oncologie Expérimentale, Centre de Recherche et Développement Pierre Fabre - Toulouse Langlade, Toulouse, France
| |
Collapse
|
10
|
Brel V, Annereau JP, Gomes B, Vandenberghe I, Andre K, Marionneau ML, Lacastaigneratte L, Stennevin A, Rouquet J, Latil A, Kruczynski A, Bailly C, Guilbaud N. Abstract B37: F14512, a polyamine-vectorized anticancer drug, triggers senescence cell death mechanism. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-b37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Drugs specifically vectorized to cancer cells may offer a reinforced activity, resulting in an improved therapeutic index. In this context, F14512 exploits the Polyamines Transport System (PTS) to accumulate into cells and exhibits an enhanced anti-proliferative activity on a large panel of tumor cell lines as compared to etoposide. At the molecular level, the spermine tail of F14512 contributes to enhance the water solubility of the drug, and reinforces the activity of the drug toward its primary molecular target, topoisomerase II. This observation has encouraged the set up of a phase 1 clinical study with F14512 in patients with relapsed or refractory acute myeloid leukemia (AML).
In order to determine how these molecular properties translate at the cellular level, we have compared the kinetic of cell cycle modulation associated with the inhibition of cell proliferation. F14512 proved to be >30-fold more cytotoxic than etoposide against A549 non-small cell lung cancer cells and triggers less but unrecoverable DNA damages and does not lead to a marked accumulation in the S-phase of the cell cycle, unlike etoposide. Interestingly, A549 cells treated with F14512 were less prone to undergo apoptosis (neither caspases-dependent, nor caspases-independent pathways) or autophagy but preferentially entered into senescence. Drug-induced senescence was characterized qualitatively and quantitatively by an increased -galactosidase activity, both by cytochemical staining and by flow cytometry. A morphological analysis by electron microscopy revealed the presence of numerous multi-lamellar and vesicular bodies and large electron-lucent vacuoles in F14512-treated cell samples. The mechanism of drug-induced cell death is thus distinct for F14512 as compared to etoposide, and this difference may account for their distinct pharmacological profiles and the superior activity of F14512 in vivo. The identification of such response markers for senescence are currently pursued on in vivo MX-1 models by following a transcriptomic analysis focused on cell death cascades including apoptosis and senescence. This study suggests that senescence markers should be considered as potential pharmacodynamic biomarkers of F14512 antitumor response, applicable in clinical trial.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B37.
Collapse
Affiliation(s)
- Viviane Brel
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | | | - Bruno Gomes
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | | | - Karine Andre
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | | | | - Alain Latil
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | |
Collapse
|
11
|
Marion F, Annereau JP, Vispe S, Vandenberghe I, Redoules F, Stennevin A, Gras S, Roy S, Castano C, Kruczynski A, Barret JM, Guilbaud N, Bailly C, Fahy J. Abstract 5461: Novel antitumor amino-pancratistatin derivatives inhibitors of protein and DNA synthesis. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-5461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The Amaryllidaceous alkaloids pancratistatin and narciclasine are known to exert marginal antitumor properties but associated with toxicities. Despite extensive investigations, pancratistatin or analogues did not succeed to provide sufficient therapeutic benefit although a new pro-drug strategy was applied recently to narciclasine. We decided to undertake a chemistry program aimed at modifying the skeleton of this attractive pharmacophore in order to improve its therapeutic application. At first sight, literature survey suggests that any change in the structure would lead to a loss of activity but a careful examination of published data indicated that position −1 of the molecule may be of potential interest although poorly investigated. We report here the synthesis of a series of 39 novel derivatives of 1-aminopancratistatin by chemical modification of the naturally available narciclasine extracted from Narcissus bulbs. These new compounds present improved pharmaceutical properties such as higher aqueous solubility (from 300 µg/ml for narciclasine up to 2000 µg/ml) without loss of stability tested on human and murine microsomal assays (70-90% stability after 1h incubation). A sub-set of these novel derivatives demonstrated a drastic increase of the cytotoxic activity reaching nM range tested on a panel of 8 different cell lines. The higher antiproliferative activity translates towards the induction of stronger pro-apoptotic signals evidenced with Annexin V, caspase 3/7 and JC-1 assay. Besides the previously described inhibition of protein synthesis, our studies originally demonstrated that part of the mechanism of action involves inhibition of DNA synthesis as well. The contribution of these two pharmacological properties elaborates a SAR (structure - activity relationship) and segregates our new pancrastistatin derivatives into different categories depending on their ability to inhibit protein synthesis, DNA synthesis or both. Based on their differential in vitro activity profile, the compounds were selected for evaluation of their in vivo antitumor properties on murine and xenografted models. As a major result F 98604 (dimethylaminomethyl benzamide derivative of pancratistatin) exhibited significant and reproducible activity on the murine B16 sc and human A375 melanoma models in terms of tumor growth inhibition as well as increased therapeutic index. The present SAR suggests that modification of the natural pancratistatin or narciclasine pharmacophore at the position −1 open new perspectives as potential anticancer agents with novel pharmacological profiles.
Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5461.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Stephane Gras
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | - Sabine Roy
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| | | | | | | | | | | | - Jacques Fahy
- 1Institut de Recherche Pierre Fabre, Toulouse, France
| |
Collapse
|
12
|
Imbert T, Guminski Y, Cugnasse S, Grousseaud M, Barret JM, Kruczynski A, Vispe S, Gras S, Annereau JP, Vandenberghe I, Stennevin A, Lacastaignaratte L, Novosad N, Pourtau S, Roy S, Castano C, Blanchet JC, Guilbaud N, Bailly C. Abstract A87: Synthesis and structure-activity relationships of a series of epipodophyllotoxin polyamine conjugated derivatives vectorized for active polyamine transporter system in tumor cells, leading to the selection of F14512 for clinical trials. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-a87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
One of the major concerns for chemotherapy is the selective targeting of drugs into highly proliferative cancer cells. Natural polyamines (spermine, spermidine, putrescine) are essential for the regulation of cellular growth and differentiation. Due to their highly proliferative nature, cancer cells have a pronounced need to import polyamines from their external environment, through the polyamine transporter system (PTS). On the basis of this biological mechanism, we vectorized the new cytotoxic anticancer compound F14512, a epipodophyllotoxin — spermine conjugate, into tumor cells.1 Here we present the synthesis and the structure-activity relationships of a new series of compounds constituted by an podophyllotoxin core tethered with a polyamine moiety with a variable spacer. Two synthetic strategies with protected polyamines, and a direct 3 steps synthesis of F14512 from natural podophyllotoxin and spermine without any protection are presented.2 This series of topoisomerase II inhibitors were checked for their cytotoxicity on A549 lung cancer cell line, displaying marked potency up to nM range. Cancer cell internalization through PTS was assessed by selective cytotoxicity on different PTS expressing cell lines, and by competition experiments. Our results displayed a potent specificity for the conjugated tetramine (spermine) compounds, which were more recognized than the triamine (spermidine) ones, while mono and diamines showed no selectivity. Lead compounds were also tested in vivo and proved potent antitumor activity. This series of new water-soluble cytotoxic compounds culminates with the selection of F14512 for clinical trials.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A87.
Collapse
Affiliation(s)
- Thierry Imbert
- 1 Division de Chimie Médicinale, Centre de Recherche Pierre Fabre, 81100 Castres, France
| | - Yves Guminski
- 1 Division de Chimie Médicinale, Centre de Recherche Pierre Fabre, 81100 Castres, France
| | - Sandrine Cugnasse
- 1 Division de Chimie Médicinale, Centre de Recherche Pierre Fabre, 81100 Castres, France
| | - Martial Grousseaud
- 1 Division de Chimie Médicinale, Centre de Recherche Pierre Fabre, 81100 Castres, France
| | - Jean-Marc Barret
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Anna Kruczynski
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Stéphane Vispe
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Stéphane Gras
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Jean-Philippe Annereau
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Isabelle Vandenberghe
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Aline Stennevin
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Laurence Lacastaignaratte
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Natacha Novosad
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Sandrine Pourtau
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Sabine Roy
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Caroline Castano
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Jean-Christophe Blanchet
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Nicolas Guilbaud
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| | - Christian Bailly
- 2 Centre de Recherche en Oncologie Expérimentale, Institut de Recherche Pierre Fabre, 31432 Toulouse, France
| |
Collapse
|
13
|
Rival Y, Stennevin A, Puech L, Rouquette A, Cathala C, Lestienne F, Dupont-Passelaigue E, Patoiseau JF, Wurch T, Junquéro D. Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J Pharmacol Exp Ther 2004; 311:467-75. [PMID: 15273253 DOI: 10.1124/jpet.104.068254] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Peroxisome proliferator-activated receptors (PPARs) regulate storage and catabolism of fats and carbohydrates. PPARgamma activity increases insulin sensitivity and adipocyte differentiation at the expense of adipogenesis and weight gain. The goal of this study was to 1) clone the promoter of the human adipocyte fatty acid binding protein (aP2) gene, namely fatty acid-binding protein-4, 2) characterize its pharmacological regulation, and 3) determine its putative predictability for adipogenesis. Among the selected PPAR agonists, rosiglitazone and pioglitazone displayed the highest maximal efficacy (E(max)) on reporter-gene assays in COS-7 cells cotransfected by either a galactosidase 4-response element-based or a human aP2 promoter-based Luc reporter vector, along with either chimeric or full-length human PPAR expression plasmids. The non-subtype-selective 2-(4-[2-(3-[2,4-difluorophenyl]-1-heptylureido)ethyl]phenoxy)-2-methyl-butyric acid (GW-2331) and the compounds [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid (L-165041), (4-((2S,5S)-5-(2-(bis(phenylmethyl)amino)-2-oxoethyl)-2-heptyl-4-oxo-3-thiazolidinyl)butyl)-benzoic acid (GW-0072), and indomethacin behaved as partial agonists relative to pioglitazone in full-length human aP2-PPARgamma2. Beyond their partial PPARgamma agonist properties, these compounds elicited a lower maximal up-regulation of mouse aP2 mRNA in 3T3-L1 adipocytes as compared with pioglitazone; these properties paralleled a time-dependent increase in neutral lipids. By contrast, the selective PPARalpha agonist 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid (BM-17.0744) neither stimulated the human aP2-PPARalpha promoter reporter-gene assay, thus demonstrating a specific interaction between PPARgamma and the aP2 promoter, nor affected lipogenesis in 3T3-L1 cells. Altogether, these data characterized a functional promoter of the human aP2 gene; its in vitro pharmacological regulation in PPARgamma-mediated reporter-gene assay may represent an interesting complement or an alternative to time-consuming procedures aiming at discriminating PPAR ligands with low lipogenic properties.
Collapse
Affiliation(s)
- Yves Rival
- Centre de Recherche Pierre Fabre, 17 Avenue Jean Moulin, 81106 Castres Cédex, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rival Y, Stennevin A, Puech L, Rouquette A, Cathala C, Dupont-Passelaigue E, Patoiseau J, Wurch T, Junquero D. W01.120 Regulation of the human αP2 promoter by PPAR modulators with various lipogenic properties. ATHEROSCLEROSIS SUPP 2004. [DOI: 10.1016/s1567-5688(04)90119-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Duplan V, Stennevin A, Ipinazar K, Druet P, Dutartre P, Saoudi A. Beneficial effect of the immunosuppressant LF 15-0195 on passively induced rat experimental autoimmune encephalomyelitis. Transplant Proc 2002; 34:2966-9. [PMID: 12431674 DOI: 10.1016/s0041-1345(02)03505-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- V Duplan
- Institut National de la Santé et de la Recherche Médicale U563 and Université Paul Sabatier, Hôpital Purpan, Toulouse, France
| | | | | | | | | | | |
Collapse
|